We remind investors that the stock was hit hard in mid-2018. Back then, Achaogen's lead drug, Zemdri (plazomicin), was approved by the FDA for the treatment of adults with complicated urinary tract infections (cUTI). However, the FDA issued a complete response letter (CRL) for another indication of Zemdri. The agency stated that the phase III

Reality Shares Nasdaq NexGen Economy China ETF (BCNA) was delisted Achaogen Inc. (AKAO) delisted to OTC and performed a ticker change to AKAOQ. Mar 27, 2019 Pharmaceutical stocks are seeing major movement in the market today. in the market today, with the spotlight shining on CRISPR Therapeutics AG (NASDAQ:CRSP), Achaogen Stock Climbing After Positive Trial Outcome. Oct 11, 2018 Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company Prior to Achaogen, he spent 13 years at Roche/Genentech in a variety of Mr. Schilke's inducement awards consist of a stock option to purchase  Jul 12, 2018 Achaogen (NASDAQ:AKAO) now looks like a very compelling investing opportunity, as this cheap Strong Buy stock just got cheaper. And now 

I-Mab, a Phase III Shanghai immunoncology-autoimmune biopharma, announced the terms for its $100 million IPO on the Nasdaq exchange at a market value of $750 million.

akao / achaogen, inc. 15-12b - - 15-12b. 08-16 sec.gov - 13 15-12b united states securities and exchange commission washington, d.c. 20549 form 15 certification and notice of termination of registration under section 12(g) of the securities exchange act of 1934 or suspension of duty to file reports under sections 13 and 15(d) of the securities Summary quote, performance, and fundamental analysis for NASDAQ:AKAO Achaogen, Inc. Investors in Achaogen, Inc. AKAO need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 15, 2017 $20 Put had some of the highest implied volatility of all equity options today. 25/04/2019 · Achaogen Inc (NASDAQ: AKAO) is flying in the market this morning. However, if you’re digging for press releases or SEC filings, you’re going to be disappointed. The company hasn’t issued any. So, what’s the deal? Today, we’ll talk about: What’s going on with AKAO stock; what we’re We remind investors that the stock was hit hard in mid-2018. Back then, Achaogen's lead drug, Zemdri (plazomicin), was approved by the FDA for the treatment of adults with complicated urinary tract infections (cUTI). However, the FDA issued a complete response letter (CRL) for another indication of Zemdri. The agency stated that the phase III During the day the stock fluctuated 0.00% from a day low at $0.10 to a day high of $0.10. Quick summary: 30 day high of the AKAO stock price was $0.10 and low was $0.10. 90 day high was $0.10 and low was $0.10. 52 week high for Achaogen - $4.84 and low - $0.06. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Achaogen, Inc. If you are looking for stocks with good return, Achaogen, Inc stock can be a bad, high-risk 1-year investment option.

Get today's Achaogen Inc stock price and latest AKAOQ news as well as Achaogen real-time stock quotes, technical analysis, full financials and more.

We have applied to have our common stock listed on The NASDAQ Global Market Underwriting Discounts and. Commissions (1). Proceeds to. Achaogen. Apr 15, 2019 Shares of Achaogen (NASDAQ: AKAO) have traded under $1 since Feb. 15 and dropped by more than 50 percent on the news to 23 cents  NASDAQ:AKAO / Achaogen, Inc. - Short Interest, Short Volume, Short short interest buy buying actual shares, which in turn drives the price up even further. Apr 15, 2019 Stock Market Quotes, Business News, Financial News, Trading Ideas, Nanocap biotech Achaogen Inc (NASDAQ: AKAO) has been pushed to 

Jun 15, 2016 Achaogen (AKAO: Nasdaq) By Wedbush ($3.79, June 13, 2016). We are upgrading Achaogen to Outperform from Neutral and increasing our 

Podívejte se na Twitteru na tweety k tématu #achaogen. Přečtěte si, co říkají ostatní, a zapojte se do konverzace. What is an IPO but an unknown/unproven business asking for your money to chase some dream of theirs debut Cidara Therapeutics (Nasdaq.CDTX) has entered into a securities purchase agreement with certain investors, in a registered…

Achaogen, a biopharmaceutical company, discovers and develops broad-spectrum IPO Status Public Stock Symbol NASDAQ:AKAO Company Type For Profit.

Take a look at the 1-year chart of Achaogen (NASDAQ: AKAO) with the added notations: AKAO has bounced on top of the $20 support (green) a couple of times during the past few months. Now that the stock has started to roll back down towards that support again, traders should be able to expect some sort of bounce. However, if the $20 support level

Reebonz (Nasdaq: RBZ) is flying early on in the trading session this morning, and for good reason. However, the company hasn’t issued any press releases.